Neurocrine biosciences announces phase 3 pediatric study results of crinecerfont in children and adolescents for the treatment of congenital adrenal hyperplasia met primary and key secondary endpoints

Cahtalyst ™ pediatric study met primary endpoint demonstrating a statistically significant decrease from baseline in serum androstenedione in children and adolescents with congenital adrenal hyperplasia key secondary endpoint demonstrated a statistically significant decrease from baseline in daily glucocorticoid dose while maintaining androgen control crinecerfont was generally well-tolerated company to host conference call and webcast today at 8:00 a.m. et with management and dr. richard auchus, professor of pharmacology and internal medicine, division of metabolism, endocrinology, and diabetes at the university of michigan  san diego , oct. 5, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced positive top-line data from the phase 3 cahtalyst™ pediatric study evaluating the efficacy, safety, and tolerability of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency.
NBIX Ratings Summary
NBIX Quant Ranking